Caliper Reports 5.5 Percent Revenue Decline; Reduces Net Loss by 37 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Caliper Life Sciences today reported 4 percent organic revenue growth amid a 5.5 percent drop in overall revenues for the third quarter. Caliper also noted that it narrowed its net loss for the quarter by 37 percent.

The Hopkinton, Mass.-based firm also said that it has been awarded a $1.8 million Phase II commitment from the Environmental Protection Agency to screen as many as 700 compounds against Caliper's ToxCast assay panel, but doesn't expect to realize this revenue until the first quarter of 2010.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.